Wegovy costs $1,349 in the US vs. $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.
Medicare moves to expand coverage for weight-loss drugs Wegovy, Zepbound
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and Zepbound.
How to preserve muscle mass on weight-loss drugs like Wegovy
There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to general weight loss. Is this a real concern, and if so, how can a person maintain their muscle mass on GLP-1 drugs?
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
What to Know About Biden’s Plan for Weight-Loss Drugs, Medicaid and Medicare
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
MedPage Today on MSN6h
IG Live December 2: The Weight of Wegovy
However, the drugs have their limits -- such as weight-loss plateaus and weight regain after stopping treatment -- and as ...
Ozempic, Wegovy Linked To Lower Hospitalizations In Alcohol Addicts, Research Shows
GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...
Exclusive: Thousands turn to Wegovy copies each month as FDA considers shortage status
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
The Columbian2d
Even with access to blockbuster obesity drugs, some people don’t lose weight
Griffin, who didn’t respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds.
Yahoo Finance1mon
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
In a trial called SURMOUNT-5, Lilly enrolled 700 people in an attempt to prove Zepbound is better than Wegovy at reducing the body mass of people with obesity or who are overweight, and have ...
Medicare Could Pay for Wegovy. Don’t Count On It.
The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration ...
BioPharma Dive1d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...